Quin-Release en es it fr

Quin-Release Brand names, Quin-Release Analogs

Quin-Release Brand Names Mixture

  • No information avaliable

Quin-Release Chemical_Formula


Quin-Release RX_link


Quin-Release fda sheet

Quin-Release FDA

Quin-Release msds (material safety sheet)

Quin-Release Synthesis Reference

No information avaliable

Quin-Release Molecular Weight

324.417 g/mol

Quin-Release Melting Point

174 oC

Quin-Release H2O Solubility

140 mg/L

Quin-Release State


Quin-Release LogP


Quin-Release Dosage Forms


Quin-Release Indication

For the treatment of ventricular pre-excitation and cardiac dysrhythmias

Quin-Release Pharmacology

Quinidine, a hydantoin anticonvulsant, is used alone or with phenobarbital or other anticonvulsants to manage tonic-clonic seizures, psychomotor seizures, neuropathic pain syndromes including diabetic neuropathy, digitalis-induced cardiac arrhythmias, and cardiac arrhythmias associated with QT-interval prolongation.

Quin-Release Absorption

No information avaliable

Quin-Release side effects and Toxicity

No information avaliable

Quin-Release Patient Information

Before prescribing QUINAGLUTE® as prophylaxis against recurrence of atrial fibrillation, the physician should inform the patient of the risks and benefits to be expected. Discussion should include the facts

  • that the goal of therapy will be a reduction (probably not to zero) in the frequency of episodes of atrial fibrillation; and
  • that reduced frequency of fibrillatory episodes may be expected, if achieved, to bring symptomatic benefit; but
  • that no data are available to show that reduced frequency of fibrillatory episodes will reduce the risks of irreversible harm through stroke or death; and in fact
  • that such data as are available suggest that treatment with QUINAGLUTE® is likely to increase the patient's risk of death.

To confirm whether this is the most current prescribing information available on Quinaglute®, or to obtain the most current prescribing information, please call Berlex Laboratories at 1-888-BERLEX-4 (choose option #4, Product Usage Information).

Quin-Release Organisms Affected

Humans and other mammals